Clinical trials: Elevated Lipoprotein(a)
Elevated LDL Cholesterol
A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol
This study evaluates the effect on LDL cholesterol of the 3 drugs given together in the cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin, and ramipril) as compared to the effect on LDL cholesterol of…
- Trial name
- NCT01004705
- Testing
- Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),, Simvastatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Ferrer Internacional S.A.
Dyslipidemia
Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)
This study will evaluate whether chronic dosing with Niaspan™ increases reverse cholesterol transport, high-density lipoprotein cholesterol (HDL-C) levels, and fecal excretion of cholesterol.
- Trial name
- NCT01071291
- Testing
- Niaspan
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
- Trial name
- NCT06292013
- Testing
- Lepodisiran Sodium
- Where
- 928 sites in United States, Argentina and 26 more
- Volunteers
- 17,300 people
- Sponsor
- Eli Lilly and Company
Acute Coronary Syndrome (ACS)
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in…
- Trial name
- NCT07625306
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
Lipoprotein Disorder
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
The main purpose of this study is to evaluate the efficacy and safety of HRS-5632 in adult participants with elevated Lipoprotein(a) (Lp(a)) at high risk for cardiovascular events.
- Trial name
- NCT07185776
- Testing
- HRS-5632 Injection
- Where
- 2 sites in China
- Volunteers
- 203 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
ASCVD, Risk Factor, Cardiovascular
Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy…
- Conditions
- ASCVD, Risk Factor, Cardiovascular, Elevated Cholesterol
- Trial name
- ORION-11 (NCT03400800)
- Testing
- Inclisiran Sodium
- Where
- 70 sites in Czechia, Germany and 5 more
- Volunteers
- 1,617 people
- Sponsor
- The Medicines Company
Obesity
High Density Lipoprotein Turnover
The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period.
- Trial name
- NCT00408148
- Testing
- Rimonabant
- Where
- 4 sites in Australia, Finland and 2 more
- Volunteers
- 64 people
- Sponsor
- Sanofi
Healthy Volunteers
A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.
In this study biomarkers in the blood after exposure to heparin in the fasted state or after a high-fat meal will be investigated.
- Trial name
- NCT05178550
- Testing
- Heparin
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Participants
A Study of LY2484595 on Pharmacokinetics in Healthy Participants
This is a 2-part study. Part 1 is to determine the safety and tolerability in healthy participants of increasing daily doses of LY2484595 for 14 days to achieve a blood level of LY2484595 much higher than what is needed for…
- Trial name
- NCT01448824
- Testing
- LY2484595, Ketoconazole
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
HDL, Drug Safety
Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)
Phase 1 Study :Safety, Immunogenicity and Dose response of ATH03, a new vaccine against the cholesterol ester transfer protein (CETP), in healthy male subjects with high density lipoprotein cholesterol (HDLc) blood concentrations…
- Trial name
- NCT01284582
- Testing
- ATH03
- Where
- Austria
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Affiris AG
Dyslipidemia, Cardiovascular Diseases
Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events
High and Very High Risk cardiovascular patient journeys seems to vary from country to country, and current understanding of the process is incomplete.
- Conditions
- Dyslipidemia, Cardiovascular Diseases, Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
- Trial name
- SANTORINI (NCT04271280)
- Testing
- Non-interventional
- Where
- 540 sites in Austria, Belgium and 12 more
- Volunteers
- 9,559 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Healthy Volunteers
A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol
This is a phase 1 study in otherwise healthy participants with high LDL cholesterol. Following multiple doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body…
- Trial name
- NCT01618916
- Testing
- LY3015014
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
HIV Infections
Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
This study will compare 2 treatments in the way they affect cholesterol levels and the amount of HIV in the blood.
- Trial name
- NCT00028301
- Testing
- Atazanavir, Lopinavir/Ritonavir
- Where
- 97 sites in United States, Argentina and 13 more
- Sponsor
- Bristol-Myers Squibb
Elevated Lipoprotein(a)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events
This is a randomized, double-blind, placebo-controlled Phase II trial evaluating the efficacy and safety of oral SAL0137 in adults with elevated Lp(a) and high cardiovascular risk.
- Trial name
- NCT07729475
- Testing
- SAL0137 Dose 1, SAL0137 Dose 2, SAL0137 Dose 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Lipoprotein Disorder
Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events
This study is designed to evaluate the efficacy and safety of HRS-5346 Tablets in participants with high cardiovascular event risk and elevated Lp(a), and to investigate the appropriate dosage of HRS-5346 Tablets
- Trial name
- NCT07767513
- Testing
- HRS-5346
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Hyperlipidemias
A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
This study is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending doses (MAD) of SGB-3403 when single administered subcutaneously to healthy volunteers and multiple administered…
- Trial name
- NCT06239714
- Testing
- SGB-3403, Atorvastatin
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suzhou Sanegene Bio Inc.
Hyperlipidemia
Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline in LDL-C when used as…
- Trial name
- MENDEL (NCT01375777)
- Testing
- Evolocumab, Ezetimibe
- Where
- 58 sites in United States, Australia and 3 more
- Volunteers
- 411 people
- Sponsor
- Amgen
Adult Participants With Elevated Lipoprotein(a)
A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)
The purpose of this study is to evaluate the efficacy and safety of SYH2068 injection in patients with elevated lipoprotein(a).
- Trial name
- NCT07640217
- Testing
- SYH2068 Dose 1, SYH2068 Dose 2, SYH2068 Dose 3
- Volunteers
- 120 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Dyslipidemia
Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels
The purpose of this study is to evaluate safety of JTT-705 and to demonstrate efficacy of JTT-705 compared with placebo when co-administered with simvastatin 40 mg in patients with low HDL
- Trial name
- NCT00688558
- Testing
- JTT-705 600 mg and simvastatin 40 mg
- Where
- Netherlands
- Volunteers
- 92 people
- Sponsor
- Shionogi Inc.
Subjects With High LDL-Cholesterol
"A Clinical Study for Evaluating the Effect of a Plant Sterol-enriched Fermented Dairy Product on Blood Lipoprotein Profile in Japanese Adults"
INVESTIGATE THE EFFECT OF A 12-WEEK CONSUMPTION PERIOD OF SINGLE DOSE A DAY OF A PLANT STEROLS-ENRICHED FERMENTED DAIRY PRODUCT ON BLOOD LIPOPROTEIN PROFILE IN JAPANESE ADULTS WITH HIGH LDL-C.
- Trial name
- NCT02268318
- Testing
- 1-Fermented Dairy Product with Phytosterols (test), 2-Fermented dairy Product with No Phytosterols (control)
- Where
- Japan
- Volunteers
- 154 people
- Sponsor
- Danone Japan